Johnson & JohnsonvsOric Pharmaceuticals

JNJ and ORIC stock compared: price, dividend, valuation and results, from SEC filings.

ORIC

Oric Pharmaceuticals, Inc.

$7.36

Value $739M

-4.42%
ORIC's page

Johnson & Johnson (JNJ) has a market value of $652B and Oric Pharmaceuticals (ORIC) $739M. Over the last year, with dividends, JNJ moved +36.6% and ORIC -35.9%. Dividend yield: JNJ 1.95%, ORIC none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    ORIC$739M

    JNJ is 882 times ORIC

  • Revenue, 12 months

    JNJ$99.3B

    ORIC–

  • Net income, 12 months

    JNJ$16.1B

    ORIC-$156M

  • Operating margin

    JNJ–

    ORIC–

  • ROIC

    JNJ12.4%

    ORIC-29.4%

    41.8 points apart

  • P/E

    JNJ40.5

    ORIC–

  • Dividend yield

    JNJ2.0%

    ORIC0.0%

    2.0 points apart

  • 5-year return

    JNJ+90.9%

    ORIC-55.4%

    146.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+90.9%

ORIC-55.4%

10020020222023202420252026
Returns by period
PeriodJNJWith dividendsORICWith dividends
1 year since November 19, 2025+36.6%Price +33.6%-35.9%Price -35.9%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%+3.1%+1.0% a yearPrice +3.1%
5 years since November 19, 2021+90.9%+13.8% a yearPrice +66.0%-55.4%-14.9% a yearPrice -55.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonORICOric Pharmaceuticals

Valuation

JNJORIC
Valuation
Price$270.47$7.36
Market value$652B$739M
Enterprise value (EV)$679B$477M
P/E40.5–
P/E, 5-year median21.9–
P/B8.02.2
EV/EBIT38.3–
Free cash flow yield3.2%–

Results and growth

JNJORIC
Results and growth
Revenue, 12 months$99.3B–
Net income, 12 months$16.1B-$156M
Free cash flow, 12 months$20.6B-$129M
Earnings per share, 12 months$6.59-$1.43
Revenue growth, year on year6.1%–
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJORIC
Margins and returns on capital
Gross margin67.6%–
Operating margin––
Net margin16.2%–
ROIC12.4%-29.4%
ROE19.7%-40.4%

Balance sheet

JNJORIC
Balance sheet
Cash$17.2B$261M
Total debt$44.7B$3.4M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJORIC
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or ORIC

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Oric Pharmaceuticals?

By market value, Johnson & Johnson ($652B) is about 882.4 times Oric Pharmaceuticals ($739M), at today's prices.

How did JNJ and ORIC stock do over the last 5 years?

Since November 19, 2021, JNJ's price moved +66.0% and ORIC's -55.4%. With dividends: JNJ +90.9% (+13.8% a year), ORIC -55.4% (-14.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or ORIC?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Oric Pharmaceuticals. Over the last twelve months they paid $5.28 and – per share.

Which is the better investment, Johnson & Johnson or Oric Pharmaceuticals?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.